Mechanisms of drug hypersensitivity reactions and the skin

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 2, Issue 1, 2008, Pages 64-71

  Kuljanac, Ilko ^a  

^a KARLOVAC GENERAL HOSPITAL   (Croatia)

Author keywords

Diagnosis; Drug hypersensitivity; Immune mechanism; The skin; Therapy

Indexed keywords

ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; IODINATED CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; SULFONAMIDE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; DELAYED HYPERSENSITIVITY; DESENSITIZATION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA MULTIFORME; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPATHOGENESIS; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; PATENT; PHOTOALLERGY; PHOTOTOXICITY; PRIORITY JOURNAL; PROVOCATION TEST; PUSTULOSIS; RISK BENEFIT ANALYSIS; SENSITIZATION; SERUM SICKNESS; SKIN ALLERGY; SKIN MANIFESTATION; SKIN TEST; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; PATENTS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN; SKIN TESTS; TIME FACTORS;

EID: 42149120136     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221308783399252     Document Type: Article

References (89)

1. Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005; 23: 171-181.
2. Jick H. Adverse drug reactions: the magnitude of the problem. J Allergy Clin Immunol 1984; 74: 555-557.
3. World Health Organization. Technical Report No. 498. Geneva. 1972.
4. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-129.
5. Rawlins MD, Thompson JW. Textbook of adverse drug reactions. Davies DM, Ed Oxford: Oxford University Press. 1997; 10-31.
6. Thien FCK. Drug hypersensitivity. MJA 2006; 185(6): 333-338.
7. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-315.
8. Aronson JK, Davidson's principles and practice of medicine. Haslen C, Chilvrts ER, Boom NA, Eds. 19th ed. Edinburgh: Elsevier Sciencs 2002; 147-163.
9. Park B, Pirmohamed M, Kitteringham N. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-395.
10. Sharma VK, Sethuraman GG. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med 1996; 42: 15-22.
11. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol 2000; 105: 637-644.
12. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003; 68: 1781-1790.
13. Greenberger PA. Drug allergy. J Allergy Clin Immunol 2006; 117: S464-470.
14. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48 (7): 1223-1244.
15. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99: 2302-2309.
16. Szebeni J. Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 2005; 216: 106-121.
17. Schiavimo D, Nucera. E, Ronacallo C, et al. Multiple-drug intorlerance syndrome: clinical findings and usefulness of challenge tests. Ann Allergy Asthma Immunol 2007; 99 (2): 136-42.
18. Sivagnanam S, Delen D. Red man Syndrome. Critical Care 2003; 7:119-20.
19. Davis RL, Smith AL, Koup JR. The red man's syndrome and slow infusion of voncomycin (Letter). Ann Intern Med 1986; 104: 285-286.
20. Coombs PR, Gell PG Clinical Aspects of Immunology Gell RR, Ed. Oxford: Oxford Universitiy Press 1968; 575-69.
21. Austey A. Drug reactions and the skin Medicine 2005; 33(1): 70-71.
22. Svensson CK, Cowen EW, Gaspari. AA. Cutaneous Drug Reactions. Pharmacol Rev 2000; 53(3): 357-79.
23. Metcalfe DD, Baram D, Mekoni YA, Mast cells. Physiol Rev 1997; 77: 1033-1079.
24. Pichler WJ. Drug Hypersensitivity Pichler WJ ed. Basel Karger 2007; 99: 168-189.
25. Descotes I, Choquet-Kastylevsky: Gell and Coombs classifications is it still valid?: Toxicology 2001; 158:43-49.
26. De Shazo RD, Kemp SF. Allergic reactions to drug and biologic agents, JAMA 1997; 278: 1805-1906.
27. Roychowdhury S, Svensson CK. Mechanisms of drug-induced delayed hypersensitivity reactions in the skin. AAPJ 2005; 7: E834-46.
28. Shushakova N, Skokova J, Schulman J, et al. C5a anaphylatoxin is a major regulator activating versus inhibitory Fc γ Rs in immune complex-induced lung disease. J Clin Invest 2002; 110: 1823-1830.
29. Pichler WJ. Delayed Drug Hypersensitivity Reactions. An Intern Med 2003; 139: 683-93.
30. Willkinson J, Rycroft R. Champion R, Burton J, Rook/Willkinson/Ebling, Textbook of dermatology, Ebling F, Eds.Oxford: Blackwell Scientific Publications 1992; 1: 622-715.
31. Marks JG Jr, DeLeo VA, Marks JG, DeLeo VA, Eds: Contact and Occupational Dermatology 1997; 42:3-14.
32. Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 2004; 194: 179-96.
33. Sebastiani S, Abanesi C, De PO, Puddu P, Cavani A, Girolamoni G. The role of chemokines in allergic contact dermatitis. Arch Dermatol Res 2002; 293: 552-59.
34. Merk H, Barow J, Hertl M, Niederaw D, Rubben A. Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds. Int Arch Allergy Immunol 1997; 113: 173-76.
35. Barranco P, Lopez-Serrano MC. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy 1998; 28(suppl. 4): 61-62.
36. Lee A, Thomson J, Lee A. Adverse Drug Reactions. 2nd ed. Pharmaceutical Press 2006; 125-56.
37. Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk for non steroid anti inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000; 84: 101-106.
38. Vervloet D, Durham S. ABC of allergies. Adverse reactiond to drugs. Br Med J 1998; 316: 1511-1513.
39. Breathnach SM, Champion RH, Burton JJ, Burns DA, Breathnach SM. Textbook of dermatology. 6th ed. London: Blackwell Science 1998; 3349-518.
40. Inamdar AC, Palit A. Serious cutaneous adverse drug reactions: Pathomechanisms and their implications to treatment. Indian J Dermatol Venereol Leprolog 2003; 169: 205-208.
41. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 305-310.
42. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfinic C, Bonati M. Incidence of adverse drug reactions in pediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Clin Pharmacol 2001; 52: 77-83.
43. Pouyanne P, Harambura F, Imbs JL, Begaud B. Admission to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036[bmj com on Dec 11; 2007].
44. McMurdo MET. Adverse drug reactions. Age Ageing 2000; 29: 5-6.
45. del Mar Campos-Fernandez M, Ponce-de-Leon-Rosales S, Archer-Dubon C, Orozco-Topete R. Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clinic 2005; 57(6): 770-74.
46. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infections. N Engl J Med 1993; 328: 1670-674.
47. Lee A, Phil M, Pharm MR, Thomson J. Adverse drug reactions: drug-induced skin reactions. Pharm J 1999; 262: 357-62.
48. Sane SP, Bhat AD. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition, and management. J Assoc Physic India 2000; 48: 999-1003.
49. McKenna JK, Leiferman KM. Dermatologic drug reactions. Immunol Allergy Clin North Am 2004; 24: 399-423.
50. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765-70.
51. Yawalkar N. Drug-induced exanthemas. Toxicology 2005; 209: 131-34.
52. Shipley D, Ormerod AD. Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol 2001; 2(3): 151-58.
53. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol 2003; 24(7): 376-79.
54. Brucner AL, Weston WL, Morelly JG. Does sensitization to contact allergens begin in infancy? Pediatrics 2000; 105: 3-6.
55. Hayakawa R. Contact Dermatis. Nagoya J Med Sci 2000; 63: 83-90.
56. Osuna H, Nishida R, Kawaguchi T, et al. Five cases of contact dermatitis spreading to the whole body-contact dermatitis syndrome and systemic contact-type dermatitis. Environ Dermatol 1997; 4: 241-48.
57. Siraganian RP, Hook WA. Complement-induced histamine release from human basophils: mechanism of the histamine release reaction. J Immunol 1976; 116: 369-646.
58. Gamarra RM, McGraw SD, Drelichman VS, Mass LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006; 30(1):41-44.
59. Vial T, Pont J, Pham E, Rabilloud R, Descotes J. Cefaclar-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacoter 1992; 26: 910-914.
60. Assier H, Bastuji-Gerin S, Revuz J. Erythema multiforme with mucous membrane involvement and Steven-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131: 539-43.
61. Sullivan JR, Shear NH. The drug hypersensitivity syndrome. What is the pathogenesis?Arch Dermatol 2001; 137: 357-64.
62. Guibal F, Bastuji-Garim S, Chosidow O, Saiag P, Revuz J, Ronjeau JC. Characteristics of toxic epidermal necrolysis in patient undergoing long-term glucocorticoid therapy. Arch dermatol 1995; 131:669-72.
63. Pichler WJ. Immune mechanism of drug hypersensitivity Immunol Allergy clin North Am 2004; 24: 373-97.
64. Sideroff A, Halevy S, Bouwes-Barinck JN, Vaillant L, Roujean JC. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001; 28(3):113-19.
65. Hitch JM. Acneiform eruptions induced by drugs and chemicals. JAMA 1967; 200: 879-80.
66. Korkij W, Soltani K. Fixed drug eruption. A brief review. Arch Dermatol 1984; 120: 520-24
67. Roucco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-12.
68. Strattow MA. Drug induced sistemic lupus erythematosus. Clin Pharm 1985; 4: 657-63.
69. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
70. Brockow K, Romano A, Bianca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
71. Pichler W, Yawalkar N, Sehmid S, Heibling A. Pathogenesis of drug-induced exanthemas. Allergy 2002; 57: 884-93.
72. Solley GO. Testing for drug allergy. Aust Prescr 1994; 17: 62-65.
73. Nyfeler B, Pichler WJ. Sensitivity and specifity of the lymphocyte transformation test to drugs. Clin Exp Allergy 1997; 27: 175-81.
74. Neukomm C, Yawalkar N, Helbling A, Pichler WJ. T-cell reactions to drugs in dinstinct clinical manifestations of drug allergy. J Invest Allergy Clin Immunol 2001; 11: 275-84.
75. Lugue I, Leyval L, Jose M, et al. T-cell responses to β-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56: 611-18.
76. Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotic. Allergy 2003; 58: 961-72.
77. Bircher AJ, Haldimann D, Weber J. CAST-ELISA testing for diagnosis of immediate-type allergic reactions to beta-lactam antibiotics. Allergy Clin Immunol Int 1996; 8: 109-10.
78. Pichler WJ, Yawalkar N, Schmid S, Helbling A. Pathogenesis of drug-induced exanthems. Allergy 2002; 57: 884-93.
79. Romano A., Blanca M, Torres MJ, et al. Diagnosis of non immediate reactions to beta-lactam antibiotics. Allergy 2004; 59: 1153-1160.
80. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58: 854-63.
81. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Drug Safety 1995; 13: 56-68.
82. Chopra A, Drage LA, Hanson EM, Touchet NL. Stevens-johnson syndrome after immunization with small pox, antrax, and tetanus vaccine mayo. Clin Proc 2004; 79: 1193-1196.
83. Jeon, S., Nahm, D.: WO06098607A1 (2006).
84. Friedman, D., Besonov, A., Tamarkin, D., Eini, M.: WO07099396A2 (2007).
85. Singh, J.: WO07016766A1 (2007).
86. Hetherington, S., Hughes, A.R., Lai, E.H., Mosteller, M. JR., Shortino, D US20070148641A9 (2007).
87. Fouillet, X.: WO07093517A1 (2007).
88. Phillips KA, Veenstra DI, Orem E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 2001; 286: 2270-279.
89. O'Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003; 4(1): 1-4.